Stocks and Investing
Stocks and Investing
Wed, December 14, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, December 13, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Christopher Raymond Maintained (AMGN) at Buy with Increased Target to $299 on, Dec 13th, 2022
Christopher Raymond of Piper Sandler, Maintained "Amgen Inc." (AMGN) at Buy with Increased Target from $297 to $299 on, Dec 13th, 2022.
Christopher has made no other calls on AMGN in the last 4 months.
There are 5 other peers that have a rating on AMGN. Out of the 5 peers that are also analyzing AMGN, 1 agrees with Christopher's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Gregory Renza of "RBC Capital" Maintained at Hold with Increased Target to $240 on, Friday, November 4th, 2022
These are the ratings of the 4 analyists that currently disagree with Christopher
- Jay Olson of "Oppenheimer" Maintained at Buy with Increased Target to $310 on, Tuesday, December 6th, 2022
- Trung Huynh of "Credit Suisse" Initiated at Sell and Held Target at $240 on, Friday, November 18th, 2022
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $282 on, Friday, November 4th, 2022
- Carter Gould of "Barclays" Downgraded from Hold to Sell and Held Target at $234 on, Monday, October 31st, 2022
Contributing Sources